Key exclusion criteria included a history, or presence, of can- cer, diabetes, or any clinically significant cardiovascular, respiratory, metabolic, renal, hepatic, gastrointestinal, endocri- nological, hematological, dermatological, venereal, neurologi- cal, psychiatric diseases, or other major disorder; previous gastrointestinal surgery; history of Crohn’s disease, ulcerative colitis, or other inflammatory bowel disease (full eligibility criteria are listed in Supplementary Online Material). Prescription or non-prescription medicinal or herbal products were not allowed within 3 weeks before or during the trial, other than the use of contraceptives, occasional use of para- cetamol (up to 3000 mg daily [3 × 1000 mg]), and use of local anesthetics for gastric pH measurement procedures. 2.2. Trial design This was a randomized, open-label, parallel-group trial (NCT02249871) conducted at a single site (Early Phase Clinical Unit, PAREXEL International GmbH, Berlin, Germany) between September 2014 and April 2015.